KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.

G Walter Canonica, Arnaud Bourdin, Anju T Peters, Martin Desrosiers, Claus Bachert, Stephan Weidinger, Eric L Simpson, Nadia Daizadeh, Zhen Chen, Siddhesh Kamat, Asif H Khan, Jingdong Chao, Neil M H Graham, Elizabeth Laws, Ana B Rossi, Marius Ardeleanu, Leda P Mannent, Nikhil Amin, Benjamin Ortiz, Yamo Deniz, Michel Djandji, Paul J Rowe

J Allergy Clin Immunol Pract 10(6) 1515-1526

PMID35259535
PMCID-
DOI10.1016/j.jaip.2022.02.026
发表日期2022-03-08
摘要

摘要

BACKGROUND: Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type 2 inflammation and has demonstrated treatment benefits in patients with atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP) with an acceptable safety profile. OBJECTIVE: This post hoc analysis across five phase 3 studies in patients with moderate to severe AD or asthma, or severe CRSwNP, evaluated time of onset and duration of the treatment response. METHODS: Patients received subcutaneous dupilumab 200/300 mg or placebo. Assessments included the Eczema Area and Severity Index, Peak Pruritus Numerical Rating Scale, and Dermatology Life Quality Index in AD; pre-bronchodilator FEV1, daily morning peak expiratory flow, and symptom scores in asthma; and University of Pennsylvania Smell Identification Test, daily nasal congestion, and loss of smell scores in CRSwNP. RESULTS: At week 2 after the initiation of dupilumab versus placebo, 67.8% versus 36.5% of AD patients achieved a clinically meaningful benefit (Eczema Area and Severity Index: 50% or greater improvement; Peak Pruritus Numerical Rating Scale: 3 point or greater improvement; or Dermatology Life Quality Index: 4 point or greater improvement) (P < .001). Moreover, 61.6% versus 39.9% of asthma patients achieved improvements in pre-bronchodilator FEV1 of 100 mL or greater and 48.8% versus 26.3% achieved 200 mL or greater improvement (both P < .001); 33.2% versus 5.6% of CRSwNP patients regained a sense of smell (P < .001). Treatment effects further improved or were sustained to the end of treatment. CONCLUSIONS: Clinically meaningful responses were achieved rapidly after the first dupilumab dose in AD, asthma, or CRSwNP and were sustained throughout treatment (see Video in this article's Online Repository at www.jaci-inpractice.org).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。